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Lifestyle and Metformin
Interventions Have a Durable
Effect to Lower CRP and tPA
Levels in the Diabetes Prevention
Program Except in Those Who
Develop Diabetes
Diabetes Care 2014;37:2253–2260 | DOI: 10.2337/dc13-2471
OBJECTIVE
We evaluate whether lifestyle and metformin interventions used to prevent di-
abetes have durable effects on markers of inflammation and coagulation and
whether the effects are influenced by the development of diabetes.
RESEARCH DESIGN AND METHODS
TheDiabetes Prevention Programwas a controlled clinical trial of 3,234 subjects at
high risk for diabetes who were randomized to lifestyle, metformin, or placebo
interventions for 3.4 years. Diabetes was diagnosed semiannually by fasting glu-
cose and annually by oral glucose tolerance testing. In addition to baseline testing,
anthropometry was performed every 6months; fasting insulin yearly; and hs-CRP,
tissue plasminogen activator (tPA), and fibrinogen at 1 year and end of study
(EOS).
RESULTS
CRP and tPA levels were unchanged in the placebo group but fell in the lifestyle
and metformin groups at 1 year and remained lower at EOS. These reductions
were not seen in those who developed diabetes over the course of the study
despite intervention. Fibrinogen was lower at 1 year in the lifestyle group. Differ-
ences in weight and weight change explained most of the influence of diabetes on
the CRP response in the lifestyle group, but only partly in the placebo and met-
formin groups. Weight, insulin sensitivity, and hyperglycemia differences each
accounted for the influence of diabetes on the tPA response.
CONCLUSIONS
Lifestyle and metformin interventions have durable effects to lower hs-CRP and
tPA. Incident diabetes prevented these improvements, and this was accounted for
by differences in weight, insulin resistance, and glucose levels.
It is well established that lifestyle and pharmacologic interventions can slow pro-
gression to type 2 diabetes in adults with impaired glucose tolerance (IGT) by
altering pathophysiological processes important in the development of diabetes
and its complications (1,2). Among these processes, activation of inflammation
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and coagulation leading to vascular dys-
function are recently recognized abnor-
malities that have been observed to
occur in prediabetic individuals (3,4).
There have been many short-term trials
of these interventions and a few reports
of 1-year interventions on markers of
inflammation and procoagulant balance
(5,6). However, little is known about the
longer-term durability of these inter-
ventions on biomarkers of these pro-
cesses and whether changes are linked
to the ability of these interventions to
slow progression to diabetes over time.
The Diabetes Prevention Program
(DPP) compared the effect of intensive
lifestyle (ILS) or metformin with placebo
on the development of diabetes in a
multicenter cohort with IGT (1). Subse-
quently, interventions were modified
and participants entered an extended
follow-up, open-label, long-term out-
come study. During the trial, hs-CRP
(as a marker of inflammation) and tissue
plasminogen activator (tPA) and fibrino-
gen (as markers of a procoagulant state)
were measured. Previous reports from
the DPP have described the baseline lev-
els of these biomarkers and their asso-
ciations with other diabetes and
cardiovascular risk factors (7), as well
as the initial effects of ILS and metfor-
min compared with the placebo group
on CRP and fibrinogen levels after 1 year
of intervention (6).
We report here the longer-term ef-
fect of metformin and ILS in the DPP
on CRP, tPA, and fibrinogen before mod-
ification of interventions occurred. In
addition, we compared these effects in
participants who did or did not develop
diabetes.
RESEARCH DESIGN AND METHODS
Participants, Interventions, and Data
Collection
This report includes 3,234 participants
in the ILS, metformin, and placebo treat-
ment arms. Individuals were recruited
based on an increased risk for develop-
ment of diabetes (1). Eligibility was
based on results of a 75-g oral glucose
tolerance test. Inclusion criteria
included a fasting plasma glucose value
of 5.3–6.9 mmol/L (#6.9 mmol/L for
American Indians), a 2-h plasma glucose
of 7.8–11.1 mmol/L following the glu-
cose load, age $25 years, and BMI
$24 kg/m2 ($22 kg/m2 for Asian Amer-
icans). Major exclusions included a
recent myocardial infarction, symptoms
of coronary heart disease, major illness,
prior diagnosis of diabetes, or use of
medications known to impair glucose
tolerance. Written informed consent
was obtained from all participants prior
to screening consistent with the Helsinki
Declaration and the guidelines of each
center’s institutional review board.
Eligible participants were randomly
assigned to one of three interventions:
metformin 850 mg twice daily, placebo
twice daily, or an intensive program of
ILS. Random treatment assignments
were stratified by clinical center and
double-blind for the metformin and pla-
cebo groups. The goals of the ILS were to
achieve and maintain a weight reduc-
tion of at least 7% of initial body weight
through consumption of a low-calorie,
low-fat diet and to engage in moderate
physical activity for at least 150 min/
week. Adherence to metformin was de-
fined as taking $80% of assigned met-
formin and adherence to lifestyle as
achieving the assigned weight loss of
#7% of randomization weight. Diabetes
was diagnosed on the basis of an annual
oral glucose tolerance test or a semian-
nual fasting plasma glucose test accord-
ing to American Diabetes Association
criteria (8). The diagnosis required con-
firmation by a second test, usually
within 6 weeks. Weight and glucose
was assessed semiannually, while fast-
ing insulin was assessed annually. The
DPP study was stopped prematurely in
May 2001 based on evidence of diabe-
tes prevention in both active treatment
groups, and an end of study (EOS) sam-
ple collection was conducted during
a 6-month period from June through
December 2001. At this time, partici-
pants entered a bridge period where
interventions were unmasked and the
lifestyle curriculum was offered in
group sessions to the other treatment
groups. CRP, tPA, and fibrinogen were
measured at DPP baseline, at the first
annual visit, and at EOS (median [25th–
75th percentile] follow-up was 3.4
[2.8–4.0] years). CRP was also mea-
sured after 6 months. We excluded
CRP, tPA, and fibrinogen measure-
ments done after the initiation of the
bridge (see below) to limit the analyses
to the period of the DPP interventions.
Since weight, glucose, and insulin mea-
surements were obtained at protocol-
specified annual visits that did not, for
the most part, coincide with the EOS
visits, these data were obtained from
annual visits conducted within a 7-month
period prior to or after the participant’s
EOS visit. Using this approach, 91.4%
of participants had weight, fasting glu-
cose, and fasting insulin results available
for analysis. These data together with
the biomarker values obtained from sam-
ples collected at the end of the study
visit are collectively referred to as the
EOS results. During 1 week in August
2001, metformin was discontinued tem-
porarily to investigate the effect of short-
term metformin washout on diabetes
incidence (9).
Biochemical Measurements
Plasma glucose was measured on a
chemistry AutoAnalyzer by the glucoki-
nase method. Insulin measurements
were performed by a polyethylene
glycol–accelerated double antibody ra-
dioimmunoassay method. hs-CRP and
fibrinogen levels in plasma were mea-
sured immunochemically using Dade
Behring reagent on the Behring Nephe-
lometer II analyzer (BN II). tPA levels
were measured in citrated plasma using
an ELISA assay (Asserachrom tPA; Diag-
nostica Stago).
Statistical Analysis
Analysis was conducted according to the
intention-to-treat principle. Compari-
sons among groups at baseline were
made using ANOVA for quantitative var-
iables and x2 test for categorical varia-
bles. Nominal P values are shown
without adjustment for multiple com-
parisons. Mixed models were used to
assess how the interventions and diabe-
tes status affected biomarker levels.
Similar mixed-effects models were also
used to evaluate whether changes in
weight, fasting insulin, or fasting glucose
could explain the effects of diabetes sta-
tus on biomarkers. We excluded data
for participants with a CRP level exceed-
ing 32mg/L (99th percentile for the pop-
ulation), as this reflects acute illness not
related to intervention.
RESULTS
Effects of Interventions on Biomarker
Levels
Table 1 shows characteristics at baseline
and follow-up according to treatment
assignment. For the metformin group,
adherence (percentage of participants
taking$80% assigned study metformin)
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was 71.6 and 49.1% at year 1 and EOS,
respectively, and for the ILS group, ad-
herence (percentage of individuals
meeting assigned goal of #7% of their
baseline weight) was 49.9 and 37.5%,
respectively. As previously reported,
weight, fasting insulin, and fasting glu-
cose fell in both the metformin and the
ILS groups by 1 year and the reductions,
except for fasting glucose, persisted un-
til EOS. CRP, tPA, and fibrinogen levels
did not differ at baseline by intervention
group and did not change significantly
during follow-up in the placebo group.
There were significant changes in bio-
markers between intervention groups
as follows.
CRP
Compared with placebo, CRP fell at 1
year by 33 and 8% in the ILS and met-
formin groups, respectively. At EOS, CRP
in the ILS group rose somewhat but
remained 20% lower than the baseline
value; in the metformin group, the CRP
was unchanged at EOS from its 1 year
value. In both ILS andmetformin groups,
CRP values at EOS were significantly
lower than the corresponding placebo
group values.
tPA
tPA levels fell by 22% at 1 year in the ILS
group and by 18% in the metformin
group versus 7% in the placebo group
and then rose similarly in both interven-
tion groups at EOS to levels that were
still significantly lower than the corre-
sponding placebo value.
Fibrinogen
Fibrinogen levels fell significantly in the
ILS group at 1 year compared with those
in the placebo and metformin groups
but showed no differences between
groups at EOS, as both placebo andmet-
formin groups showed a fall in levels.
Comparison of Weight, Glucose,
Insulin, and Biomarker Values in
Those With and Without Incident
Diabetes
To determine whether the values of
these three biomarkers differed in par-
ticipants who developed diabetes
among the intervention groups, the par-
ticipants were divided into those who
developed diabetes versus those who
did not at each of the follow-up time
points. At 1 year, 37, 80, and 123 partic-
ipants in the ILS, metformin, and pla-
cebo groups, respectively, developed
diabetes; 141, 216, and 293, respec-
tively, had been diagnosed with diabe-
tes at EOS. Table 2 shows the absolute
biomarker values by presence/absence
of diabetes at each time point. Weight
was consistently greater in those with
diabetes compared with those without
in the ILS group only, whereas fasting
glucose and insulin were greater in par-
ticipants who had developed diabetes in
all three intervention groups. All three
biomarkers were numerically higher in
each of the intervention subgroups
that developed diabetes than their
counterparts without diabetes; differ-
ences were statistically significant at
EOS for tPA for all groups, for tPA in
the ILS group at 1 year, and for fibrino-
gen in the placebo group.
Effect of Interventions by Presence or
Absence of Incident Diabetes on
Biomarker Change
Figure 1 shows the biomarker changes
from baseline for the three intervention
groups according to the presence or ab-
sence of a diabetes diagnosis before the
assessment.
CRP
There were no changes in CRP levels
among participants either with or with-
out diabetes in the placebo group.
Among those who had not developed
diabetes in the metformin and ILS
groups, there was a significant reduction
in CRP at both 1 year and EOS, whereas
there were no changes in CRP in either
ILS ormetformin group participants who
had developed diabetes.
tPA
The tPA value was reduced overall and
among those without diabetes in the
placebo group at 1 year but was signifi-
cantly increased above baseline at EOS,
with the elevation accounted for by the
Table 1—Characteristics by treatment group
Placebo Metformin Lifestyle
n
Baseline 1,082 1,073 1,079
Year 0.5 1,019 1,024 1,044
Year 1 1,021 1,013 1,019
EOS 858 860 899
Weight (kg)
Baseline 94.3 (93.1, 95.5) 94.3 (93.1, 95.5) 94.1 (92.8, 95.3)
Year 0.5 93.7 (93.4, 94.0) 91.8 (91.5, 92.1)* 87.4 (87.1, 87.7)†,‡
Year 1 93.6 (93.3, 94.0) 91.4 (91.0, 91.7)* 87.3 (87.0, 87.7)†,‡
EOS 94.3 (93.9, 94.8) 92.6 (92.1, 93.0)* 90.3 (89.9, 90.8)†,‡
Fasting glucose (mmol/L)
Baseline 5.92 (5.90, 5.95) 5.91 (5.88, 5.94) 5.90 (5.87, 5.93)
Year 0.5 5.92 (5.89, 5.95) 5.69 (5.66, 5.72)* 5.65 (5.62, 5.68)†
Year 1 5.95 (5.91, 5.98) 5.68 (5.64, 5.72)* 5.64 (5.60, 5.68)†
EOS 6.23 (6.17, 6.29) 5.94 (5.88, 6.00)* 5.97 (5.91, 6.03)†
Fasting insulin (pmol/L)
Baseline 161 (156, 167) 163 (158, 168) 158 (153, 163)
Year 1 164 (160, 169) 138 (135, 142)* 124 (121, 128)†,‡
EOS 164 (159, 170) 147 (142, 152)* 140 (135, 144)†
CRP (mg/L)
Baseline 3.52 (3.30, 3.75) 3.34 (3.13, 3.57) 3.53 (3.31, 3.76)
Year 0.5 3.50 (3.35, 3.66) 3.09 (2.96, 3.23) * 2.78 (2.66, 2.90)†,‡
Year 1 3.40 (3.25, 3.55) 2.99 (2.86, 3.12)* 2.36 (2.26, 2.46)†,‡
EOS 3.44 (3.27, 3.62) 2.98 (2.83, 3.14)* 2.82 (2.68, 2.96)†
tPA (ng/mL)
Baseline 11.40 (11.16, 11.64) 11.25 (10.99, 11.50) 11.34 (11.09, 11.60)
Year 1 10.60 (10.43, 10.78) 9.23 (9.06, 9.41)* 8.82 (8.64, 8.99)†,‡
EOS 11.75 (11.51, 11.99) 10.70 (10.46, 10.94)* 10.71 (10.47, 10.94)†
Fibrinogen (mmol/L)
Baseline 386 (381, 391) 380 (375, 385) 385 (380, 390)
Year 1 387 (384, 391) 383 (379, 387) 374 (370, 378)†,‡
EOS 376 (371, 381) 372 (368, 377) 372 (367, 377)
Data are expressed as mean and 95% CI except for fasting insulin and CRP, which are expressed
as the geometric mean. *P, 0.05 for placebo vs. metformin. †P, 0.05 for placebo vs. lifestyle.
‡P , 0.05 for metformin vs. lifestyle.
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subgroup with diabetes. There were re-
ductions in tPA among participants
both without and with diabetes at 1
year in the ILS and metformin groups.
At this time, the fall in tPA was signifi-
cantly greater in those without diabetes
compared with those with diabetes in
the ILS group, but there were no differ-
ences between those with or without
diabetes in the metformin group. In
both metformin and ILS groups, tPA lev-
els remained significantly lower than
baseline at EOS among those without
diabetes, although they trended upward
from the 1-year values. For those with
diabetes at EOS, there was no change
in tPA levels from baseline in the met-
formin group, and there was a signifi-
cant increase above baseline in the ILS
group.
Fibrinogen
At 1 year, fibrinogen levels did not
change in the placebo or metformin
groups but decreased significantly in
ILS participants due to reductions in
those who had not developed diabetes.
At EOS, fibrinogen levels were reduced
in those without diabetes in all three
groups, but there were no changes
from baseline among participant sub-
groups that had developed diabetes.
Effect of Weight, Fasting Insulin, and
Glucose on Time-Related Biomarker
Differences According to Presence/
Absence of Incident Diabetes
CRP, tPA, and fibrinogen levels are
strongly influenced by weight, insulin re-
sistance, and glycemia measures (7). We
next used mixed modeling to assess the
contributory influences of intervention-
and time-related changes in weight,
fasting insulin as a surrogate marker
of insulin resistance, and fasting glucose
on thedifferences in biomarker responses
between those with versus without in-
cident diabetes (Table 3). There was no
interaction between the interven-
tions and the effect of incident diabetes
on CRP, tPA, or fibrinogen time-related
changes. Significant effects of the pres-
ence of diabetes on the biomarker
response to the interventions in the
basic model (model 1) are shown by em-
boldened text in Table 3. Additional
adjustment for metformin or lifestyle
adherences did not change the diabetes
effect in model 1. Although the R2 in
model 1 was small in each case, the ad-
dition of weight, insulin resistance, or
glycemia variables to model 1 accounted
for the diabetes effect on CRP and tPA
responses to interventions as indicated
by a loss of significance of the diabetes
effect noted in model 1 as follows.
CRP Change
The estimated diabetes effect for CRP
change was not influenced by baseline
or change in insulin resistance in any in-
tervention group (model A3, Table 3). In
contrast, weight partly accounted for
the effect of developing diabetes on
CRP changes in the placebo and metfor-
min groups and fully accounted for it in
the ILS group (model A4). Baseline and
changes in glucose also completely ac-
counted for the effect of diabetes on
time-related CRP change (model A5).
tPA Change
Baseline and changes in insulin and
weight partially accounted for the effect
of diabetes on the tPA change over
time (models B3 and B4), and glucose
accounted for most of the effect of
Table 2—Characteristics by diabetes or nondiabetes status and by intervention group
Placebo Metformin Lifestyle
Diabetes Nondiabetes Diabetes Nondiabetes Diabetes Nondiabetes
n
Year 0.5 38 987 10 1,018 9 1,037
Year 1 123 898 80 934 37 985
EOS 293 595 216 644 141 786
Weight (kg)
Year 0.5 95.8 (94.8, 96.9) 93.8 (93.6, 94.1) 93.2 (91.3, 95.1) 91.8 (91.6, 92.0) 93.7 (91.4, 96.1) 87.2 (86.8, 87.5)
Year 1 94.3 (93.6, 94.9) 93.7 (93.4, 94.0) 92.3 (91.5, 93.0) 91.3 (91.0, 91.6) 89.0 (87.8, 90.2) 87.1 (86.7, 87.5)
EOS 95.0 (94.3, 95.7) 94.3 (93.8, 94.8) 92.7 (91.9, 93.5) 92.5 (92.1, 93.0) 91.4 (90.4, 92.4) 89.9 (89.4, 90.5)
0’ Glucose (mmol/L)
Year 0.5 7.01 (6.85, 7.17) 5.89 (5.85, 5.92) 6.92 (6.63, 7.21) 5.68 (5.65, 5.71) 7.13 (6.84, 7.42) 5.63 (5.60, 5.66)
Year 1 6.58 (6.46, 6.70) 5.86 (5.82, 5.91) 6.23 (6.12, 6.34) 5.64 (5.60, 5.67) 6.17 (6.01, 6.33) 5.60 (5.57, 5.64)
EOS 6.80 (6.68, 6.91) 5.98 (5.90, 6.06) 6.31 (6.22, 6.41) 5.82 (5.76, 5.87) 6.82 (6.70, 6.95) 5.81 (5.76, 5.86)
0’ Insulin (pmol/L)
Year 1 197 (182, 212) 160 (156, 165) 160 (146, 176) 138 (134, 142) 178 (153, 207) 121 (118, 125)
EOS 181 (172, 191) 157 (151, 163) 163 (153, 173) 144 (139, 149) 185 (171, 199) 131 (127, 136)
CRP (mg/L)
Year 0.5 4.21 (3.51, 5.06) 3.56 (3.42, 3.71) 4.86 (3.30, 7.16) 2.99 (2.86, 3.13) 2.86 (1.83, 4.47) 2.79 (2.66, 2.92)
Year 1 3.67 (3.30, 4.08) 3.45 (3.31, 3.61) 3.26 (2.85, 3.72) 2.88 (2.75, 3.01) 2.85 (2.31, 3.51) 2.35 (2.24, 2.46)
EOS 3.69 (3.42, 3.99) 3.45 (3.26, 3.65) 3.03 (2.76, 3.34) 2.86 (2.70, 3.03) 3.11 (2.74, 3.53) 2.78 (2.63, 2.95)
tPA (ng/dL)
Year 1 10.9 (10.4, 11.4) 10.6 (10.4, 10.8) 9.7 (9.2, 10.3) 9.1 (9.0, 9.3) 10.2 (9.3, 11.0) 8.8 (8.6, 8.9)
EOS 12.4 (12.0, 12.8) 11.5 (11.2, 11.8) 11.2 (10.7, 11.7) 10.5 (10.2, 10.8) 11.5 (11.0, 12.1) 10.6 (10.3, 10.8)
Fibrinogen (mmol/L)
Year 1 397 (386, 408) 389 (385, 393) 387 (374, 400) 379 (375, 383) 386 (366, 406) 374 (371, 378)
EOS 385 (377, 394) 375 (369, 380) 377 (367, 386) 367 (362, 372) 377 (365, 390) 371 (366, 376)
Data are expressed as mean (95% CI) except for fasting insulin and CRP, which are expressed as geometric mean with adjustment for baseline levels.
Data in bold indicate significant difference between the diabetes versus nondiabetes levels within the treatment group (P , 0.05).
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diabetes on tPA change in all three in-
tervention groups (model B2).
Fibrinogen Change
Incident diabetes had no significant ef-
fect on fibrinogen changes in the met-
formin or ILS groups in this analysis
(model C1). There was a significant ef-
fect in the placebo group that was only
partly accounted for by glucose (model
C2).
CONCLUSIONS
We previously showed that ILS and met-
formin interventions lowered CRP levels
but not fibrinogen compared with pla-
cebo after 1 year of follow-up in subjects
with IGT in the DPP (6), and we now
show that lowered CRP and tPA levels
at 1 year persisted after 3.4 years of
follow-up. Previous studies have
demonstrated beneficial effects of life-
style change or metformin on CRP or
tPA, but few have evaluated these
effects beyond 1 year, and none have
compared the these effects in a long-
term controlled clinical trial. Baseline
CRP levels correlated strongly with
body weight in the DPP (7), and the ef-
fect of ILS to reduce CRP by 33% after
1 year is likely to be related to the
weight change in the ILS (6). Weight
loss in the ILS reached its nadir at
6months through 1 year and then began
to increase, though remaining signifi-
cantly reduced from baseline at EOS.
This pattern closely resembled the CRP
response to the ILS intervention. Inter-
estingly, CRP levels continued to fall
from 6 to 12 months despite no further
weight reduction after 6 months, sug-
gesting that the benefit associated
with ILS intervention or weight reduc-
tion on CRP levels extends beyond the
period of active weight loss. The less
robust initial CRP reduction in the met-
formin group at 1 year may be related to
the smaller degree of weight loss
achieved with this intervention, but
the CRP reduction remained stable
through the EOS in these participants
as compared with that in the ILS group,
which tended to attenuate. Some stud-
ies of metformin treatment have not
noted an associated fall in CRP, and
this may reflect the absence of signifi-
cant weight loss in short-term studies
(10). The similarity of CRP levels in the
ILS and metformin groups at the EOS is
of interest considering the fact that
mean weight was significantly lower
and the physical activity level consider-
ably higher at this time point in the ILS
than the metformin group (1). This sug-
gests that metformin may have long-
term effects on CRP beyond weight
reduction. The fact that CRP levels
remained lower than baseline values
for an average of 3.4 years is consistent
with a durable anti-inflammatory effect
of both ILS and metformin treatment in
the DPP.
The Finnish Diabetes Prevention Study
(FDPS) reported that lifestyle interven-
tion lowered levels of plasminogen
Figure 1—Mean (95% CI) change from baseline in CRP, fibrinogen, and tPA according to DPP intervention group, diabetes status, and time of
assessment.
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activator inhibitor 1 (PAI-1), a key endog-
enous fibrinolysis inhibitor, by 31% after
1 year, persisting for 3 years in a small
subgroup, while fibrinogen values were
not affected (5). Similarly, we found that
tPA, which was used as a surrogate mea-
sure of PAI-1 (11), fell by 21% in the ILS
group and 18% in the metformin group
at 1 year. tPA then tended to rise toward
baseline values, suggesting an attenua-
tion of the effects of these interventions.
The similarities in response of tPA to the
two interventions argues against weight
reduction being the sole determinant of
these changes since the amount of
weight reduction in ILS was greater
than with metformin. tPA remained sig-
nificantly lower than the baseline values
at EOS, suggesting that there was a per-
sisting favorable change in coagulation
balance in both active intervention
groups. No net effect of either interven-
tion on fibrinogen was noted, as has pre-
viously been reported (5,6). How long
these effects persist was not tested in
this study. We chose to focus on the
masked phase of the DPP to avoid the
confounding effects of the alteration of
the interventions that occurred with the
launching of the long-term DPP outcome
study.
A new finding in this study not appar-
ent in the overall response of the DPP
cohort was the lack of durable effects of
ILS or metformin intervention on bio-
marker levels in participants who devel-
oped diabetes versus those who did not.
One obvious explanation for this is that
those who developed diabetes were less
successful with the interventions than
those who did not. This is likely the
case for ILS, where the amount of
weight reduction was shown to be in-
versely proportional to the incidence
of diabetes (12). Because those who de-
veloped diabetes in the DPP did not on
average lose weight, and since weight
is a powerful determinant of CRP levels,
this could explain why CRP did not fall
with the ILS intervention over time in
this subgroup. In support of this, when
baseline and change in weight were
entered into amodel assessing the influ-
ence of diabetes development on time-
related CRP changes in the ILS group,
the effect of diabetes was completely
accounted for. Furthermore we did not
find evidence that developing diabetes
in the placebo group was accompanied
by an increase in CRP from baseline or
that CRP was higher in those with dia-
betes versus without diabetes. This
suggests that the major factor underly-
ing subclinical inflammation in newly
developed diabetes is overweight.
The diminished tPA response to ILS in
the subgroup that developed diabetes
was partly accounted for by weight
and fasting insulin, in keeping with our
previous observation that baseline tPA
levels in DPP independently associate
with each of these two variables (7). In
the FDPS, the reduction in PAI-1 was
largely accounted for by weight reduc-
tion. There remained a significant inde-
pendent effect of diabetes development
on the lack of reduction in tPA levels in
the ILS groups, mostly accounted for by
entering fasting glucose into the model.
Hyperglycemia has been shown to in-
crease PAI-1 expression through activa-
tion of the hexosamine pathway (13).
The lack of a reduction in CRP and tPA
levels in those who developed diabetes
in the metformin arm is less easy to ex-
plain on the basis of reduced adherence
to treatment since the major mecha-
nism by which metformin slows diabe-
tes development is thought to involve
inhibition of hepatic glucose produc-
tion, which is not directly associated
with CRP or tPA/PAI-1 levels. However,
the effect of metformin to reduce
Table 3—Adjusted effect of diabetes status on CRP, fibrinogen, and tPA by treatment group
Placebo Metformin Lifestyle
Diabetes b Diabetes R2 Diabetes b Diabetes R2 Diabetes b Diabetes R2
Outcome: CRP
Model A1: baseline CRP 20.09 (20.16, 20.02) 0.28% 20.10 (20.19, 20.01) 0.29% 20.13 (20.25, 20.01) 0.27%
Model A2: A1 + 0’ glucose 20.04 (20.11, 0.04) 0.04% 20.05 (20.14, 0.04) 0.07% 20.031 (20.16, 0.09) 0.01%
Model A3: A1 + 0’ insulin 20.09 (20.17, 20.01) 0.26% 20.12 (20.22, 20.02) 0.34% 20.13 (20.26, 20.002) 0.27%
Model A4: A1 + weight 20.06 (20.13, 0.01) 0.13% 20.08 (20.16, 0.01) 0.18% 20.01 (20.13, 0.10) 0.00%
Model A5: fully adjusted 20.04 (20.13, 0.04) 0.06% 20.07 (20.16, 0.03) 0.11% 20.02 (20.16, 0.11) 0.01%
Outcome: tPA
Model B1: baseline tPA 20.60 (20.99, 20.21) 0.50% 20.68 (21.1, 20.24) 0.53% 21.1 (21.6, 20.56) 0.98%
Model B2: B1 + 0’ glucose 20.23 (20.64, 0.18) 0.07% 20.22 (20.67, 0.23) 0.05% 20.31 (20.86, 0.24) 0.07%
Model B3: B1 + 0’ insulin 20.48 (20.88, 20.08) 0.33% 20.52 (20.95, 20.08) 0.32% 20.80 (21.3, 20.26) 0.53%
Model B4: B1 + weight 20.44 (20.82, 20.05) 0.29% 20.51 (20.92, 20.09) 0.34% 20.52 (21.0, 20.01) 0.24%
Model B5: B1 + fully
adjusted 20.14 (20.54, 0.27) 0.03% 20.16 (20.59, 0.27) 0.03% 20.11 (20.64, 0.42) 0.01%
Outcome: Fibrinogen
Model C1: baseline
fibrinogen 210 (219, 22.1) 0.35% 29.0 (218, 0.05) 0.24% 27.4 (219, 4.3) 0.10%
Model C2: C1 + 0’ glucose 28.8 (217, 20.03) 0.22% 25.4 (215, 3.9) 0.08% 24.7 (217, 7.7) 0.03%
Model C3: C1 + 0’ insulin 210 (219, 21.9) 0.35% 28.7 (218, 0.49) 0.22% 25.8 (218, 6.1) 0.06%
Model C4: C1 + weight 29.5 (218, 21.1) 0.29% 28.2 (217, 0.88) 0.20% 25.6 (218, 6.5) 0.05%
Model C5: C1 + fully
adjusted 28.5 (217, 0.41) 0.21% 25.1 (215, 4.3) 0.07% 25.7 (218, 6.9) 0.05%
The adjusted effect of diabetes on CRP, fibrinogen, and tPA over time are assessed separately for each treatment group in a series of five mixed
models that include demographics (age, sex, and race/ethnicity), year of assessment, and the baseline value of the outcome (series 1); baseline and
change in fasting glucose (series 2); baseline and change in fasting insulin (series 3); baseline and change in weight (series 4); and baseline levels and
changes in fasting glucose, fasting insulin, and weight (series 5). Estimates of the diabetes effect in bold indicate significant b for diabetes ata = 0.05.
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diabetes development in the DPP is also
related to weight reduction and possibly
to improvement in insulin sensitivity
(14). Participants who developed diabe-
tes in the metformin group were, how-
ever, of similar weight to those without
diabetes, although fasting insulin levels
were higher in those with diabetes. In
the multivariate model, in contrast to
the ILS group, weight only partly ac-
counted for the lack of a time-related
decrease in CRP in the metformin sub-
group with diabetes, with insulin having
no effect. Thus there remained a signif-
icant residual independent effect of di-
abetes development on the lack of a CRP
response to metformin that was ac-
counted for by fasting glucose.
The effect of diabetes development
on change in tPA in themetformin group
showed some similarities but also some
differences from that in the ILS group.
Weight and insulin each partly ac-
counted for the attenuation in reduc-
tion of tPA levels related to incident
diabetes and glucose explained most
of the residual effect in the two groups.
However, unlike in the placebo and life-
style groups where tPA levels increased
above baseline at the EOS, tPA levels
were no different from baseline in the
metformin group. Metformin appeared
to prevent this progressive rise in tPA
despite the development of diabetes.
This may be related to its known effect
to inhibit PAI-synthesis through a tumor
necrosis factor-a–dependent pathway
(15,16). We also considered whether
the temporary 1-week discontinuation
of metformin during the final 6-month
sampling period to evaluate the effect
of a metformin washout on diabetes de-
velopment could have influenced re-
sults (9). It is possible that tPA levels
may have increased during the metfor-
min washout, but since this would have
been transient, affected both those with
and without diabetes, and constituted
no more than a 5% fraction of the entire
metformin cohort, the potential con-
founding was considered minimal. Sim-
ilarly even though the 20 excess cases of
diabetes directly attributable to the
washout may have behaved aberrantly
with respect to their effect on bio-
markers, they represented less than
10% of cases with incident diabetes in
the metformin group. Other limitations
of the study as a whole include the fact
that there were fewer participants at
the end of the study than at the begin-
ning and that the timing of sampling for
the EOS biomarker measurements and
that of the rest of the data collection
could have been up to 7 months apart,
although 89% of samples were collected
halfway through that period.
Importantly our findings demonstrate
that over the 3.4-year period of follow-
up, tPA, but not CRP or fibrinogen, levels
progressively increase from baseline in
both the placebo and ILS but not met-
formin groups in those who develop di-
abetes and that prevention of diabetes
by ILS and metformin is accompanied by
lowered CRP and tPA levels. The pro-
gressive increase in tPA values in the
placebo and ILS subgroups with diabe-
tes resembles the pattern described
previously in this setting for more tradi-
tional cardiovascular risk factors (17),
consistent with the appearance of dys-
functional fibrinolysis and enhanced
cardiovascular risk early on in those pro-
gressing to diabetes. In this respect, tPA
may be more closely linked to diabetes
development than CRP, which is more
strongly related to weight change. The
effect of metformin treatment to pre-
vent the increase of tPA noted in the
other two subgroups with diabetes pro-
vides support for the use of metformin
at the earliest stages of diabetes devel-
opment, perhaps even if it is not able to
prevent the emergence of diabetes.
In summary, we show that in subjects
with IGT receiving metformin or lifestyle
interventions who do not develop dia-
betes, there are durable reductions in
biomarkers of inflammation and coagu-
lant imbalance. In contrast, those indi-
viduals who develop diabetes do not
experience these apparently beneficial
effects and may rapidly show unfavor-
able changes. Our analysis suggests that
failure to lose weight among those who
developed diabetes explains the lack of
reduction of CRP. Lack of weight loss or
failure of insulin sensitivity to improve
were important but not sufficient ex-
planations to account for the lack of re-
duction of tPA in those who progress to
diabetes. This could mean that rising
glucose levels per se or other associated
metabolic factors could interfere with
the beneficial effects of lifestyle or met-
formin interventions on tPA. It is also
possible that subjects who develop di-
abetes may inherently not respond as
well to these interventions. Whatever
the explanation, the higher CRP or tPA
levels in those who develop diabetes de-
spite ILS or metformin intervention is
consistent with the notion that ongoing
inflammatory and procoagulant activi-
ties accompany diabetes development
and that prevention of diabetes through
lifestyle or metformin intervention
ameliorates these processes.
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